3 results
Approved WMOCompleted
Primary: to assess the effect of intravenous (IV) ozanezumab (15 mg/kg once every 2 weeks) compared to placebo on the physical function and survival of ALS patients over a treatment period of 48-weeks.Secondary (major): other clinical outcomes,…
Approved WMOCompleted
To determine the MTD toxicity of standard dose cetuximab together with concurrent individualized, isotoxic accelerated radiotherapy and cisplatin-vinorelbine.
Approved WMOCompleted
Is the BOLD MRI able to show the difference in the level of oxygenation as a mesurement of ischemia between a in a healthy kidney (<30% renal artery stenosis) and a kidney with more than 70% artery stenosis?